| Dapagliflozin and cardiovascular outcomes in type 2 diabetes SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... New England Journal of Medicine 380 (4), 347-357, 2019 | 5871 | 2019 |
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus BM Scirica, DL Bhatt, E Braunwald, PG Steg, J Davidson, B Hirshberg, ... New England Journal of Medicine 369 (14), 1317-1326, 2013 | 4222 | 2013 |
| SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome … TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ... The Lancet 393 (10166), 31-39, 2019 | 2647 | 2019 |
| Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes M Husain, AL Birkenfeld, M Donsmark, K Dungan, FG Eliaschewitz, ... New England Journal of Medicine 381 (9), 841-851, 2019 | 1425 | 2019 |
| Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial BM Scirica, E Braunwald, I Raz, MA Cavender, DA Morrow, P Jarolim, ... Circulation 130 (18), 1579-1588, 2014 | 874 | 2014 |
| Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal … TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich, RHM Furtado, ... Circulation 139 (17), 2022-2031, 2019 | 700 | 2019 |
| Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial O Mosenzon, SD Wiviott, A Cahn, A Rozenberg, I Yanuv, EL Goodrich, ... The lancet Diabetes & endocrinology 7 (8), 606-617, 2019 | 678 | 2019 |
| Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus ET Kato, MG Silverman, O Mosenzon, TA Zelniker, A Cahn, RHM Furtado, ... Circulation 139 (22), 2528-2536, 2019 | 622 | 2019 |
| Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled … PM O'Neil, AL Birkenfeld, B McGowan, O Mosenzon, SD Pedersen, ... The Lancet 392 (10148), 637-649, 2018 | 618 | 2018 |
| Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial D Rubino, N Abrahamsson, M Davies, D Hesse, FL Greenway, C Jensen, ... Jama 325 (14), 1414-1425, 2021 | 614 | 2021 |
| Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial S Del Prato, SE Kahn, I Pavo, GJ Weerakkody, Z Yang, J Doupis, ... The Lancet 398 (10313), 1811-1824, 2021 | 377 | 2021 |
| Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction: subanalysis from the DECLARE-TIMI 58 Trial RHM Furtado, MP Bonaca, I Raz, TA Zelniker, O Mosenzon, A Cahn, ... Circulation 139 (22), 2516-2527, 2019 | 337 | 2019 |
| Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial TA Zelniker, MP Bonaca, RHM Furtado, O Mosenzon, JF Kuder, ... Circulation 141 (15), 1227-1234, 2020 | 323 | 2020 |
| Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised … P Dandona, C Mathieu, M Phillip, L Hansen, SC Griffen, D Tschöpe, ... The lancet Diabetes & endocrinology 5 (11), 864-876, 2017 | 304 | 2017 |
| Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial O Mosenzon, G Leibowitz, DL Bhatt, A Cahn, B Hirshberg, C Wei, KA Im, ... Diabetes care 40 (1), 69-76, 2017 | 281 | 2017 |
| Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial O Mosenzon, TM Blicher, S Rosenlund, JW Eriksson, S Heller, OH Hels, ... The lancet Diabetes & endocrinology 7 (7), 515-527, 2019 | 251 | 2019 |
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial JA Udell, DL Bhatt, E Braunwald, MA Cavender, O Mosenzon, PG Steg, ... Diabetes care 38 (4), 696-705, 2015 | 217 | 2015 |
| The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... American heart journal 200, 83-89, 2018 | 179 | 2018 |
| CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries O Mosenzon, A Alguwaihes, JLA Leon, F Bayram, P Darmon, TME Davis, ... Cardiovascular Diabetology 20, 1-13, 2021 | 161 | 2021 |
| DECLARE‐TIMI 58: participants’ baseline characteristics I Raz, O Mosenzon, MP Bonaca, A Cahn, ET Kato, MG Silverman, ... Diabetes, Obesity and Metabolism 20 (5), 1102-1110, 2018 | 151 | 2018 |
Deepak L. Bhatt, MD, MPH, MBADr. Valentin Fuster Professor of Cardiovascular Medicine, Icahn School of Medicine at Mount Sinai在 post.harvard.edu 的电子邮件经过验证
